NSCLC Clinical Trial
Official title:
Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma
Phase I dose escalating trial. Primary objective of this study is to define the maximal tolerated dose (MTD)of Olaparib in combination with high dose radiotherapy with or without daily dose Cisplatin in locally advanced NSCLC. Secondary objectives include to define safety profile, determine PK/Pd variables and document preliminary evidence of objective tumor response.
Concurrent chemoradiotherapy (CCRT) is the treatment of choice for patients with locally
advanced NSCLC. The cure rates however need to be improved. The main mechanism by which both
radiation and Cisplatin kill tumor cells is by an accumulation of un- or misrepaired DNA
damage.PARP inhibitors increase radiation and chemotherapy (Cisplatin) response in
preclinical studies including lung cancer models.
This open label dose escalating trial consists of a screening phase, a treatment phase and a
follow up phase.
The screening phase: patients who can tolerate concurrent cisplatin will receive Olaparib, RT
and Cisplatin. Patients who can not tolerate concurrent cisplatin will receive Olaparib and
RT with or without prior sequential chemotherapy.
The treatment phase:dose escalation of Olaparib will be performed in cohorts of 3 subjects.
The decision to escalate to the next dose level will be based on the occurrence of DLTs
during the DLT evaluation period (i.e. 3 months following the last day of irradiation) and
will be made after all patients within the cohort have completed their third month of follow
up.
Active follow-up phase: frequent follow up will take place during the first 3 months (acute
toxicity). Thereafter patients will be monitored for late toxicity and for disease activity
3-monthly throughout the first year and thereafter 6-monthly until 5 years, when patients are
deemed to be cured and follow up is no longer warranted.
Olaparib will be given orally BID for 36 consecutive days, administrated with a 12 hour
interval. Olaparib will start 2 days before start of RT and will continue for 2 days after
the last RT fraction. Olaparib is also given during the non-radiotherapy days but no
maintenance treatment is given after radiotherapy is finished.
Radiotherapy (for all patients): a total dose of 66Gy will be given in 24 fractions from week
1 to 5.
Cisplatin (concurrent chemoradiotherapy): daily dose Cisplatin 6mg/m2 (5 days/week), 1-1.5 hr
before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05821933 -
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03269162 -
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
|
Phase 3 | |
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06315686 -
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
|
Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Recruiting |
NCT05466149 -
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03609918 -
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
|
||
| Recruiting |
NCT06043817 -
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05078931 -
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05547737 -
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
| Withdrawn |
NCT05959473 -
EGFR_IUO 3.20 Clinical Study Protocol
|
N/A | |
| Not yet recruiting |
NCT05005468 -
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
|
Phase 2 | |
| Recruiting |
NCT01690390 -
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
|
Phase 2 | |
| Completed |
NCT01852578 -
Cabazitaxel in Relapsed and Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
| Completed |
NCT00702975 -
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
|
Phase 2 | |
| Completed |
NCT00866970 -
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
|
Phase 2 |